Publication | Closed Access

Enhancing the value of PCSK9 monoclonal antibodies by identifying patients most likely to benefit. A consensus statement from the National Lipid Association

Clinical ImmunologyPcsk9 Monoclonal AntibodiesMedicineImmunologyPathologyAutoimmunityHyperlipidemiaConsensus StatementImmunotherapyMolecular DiagnosticsLipid DisorderNational Lipid AssociationImmunological Biomarkers